On December 10, GENSCRIPT BIO (01548.HK) announced that on December 10, 2024 (before the trading session in Hong Kong on December 10), Legend Biotech released a press release, announcing the latest data from the Phase 3 study CARTITUDE-4. The study results indicate that in patients with relapsed or lenalidomide-refractory multiple myeloma who had received at least one line of treatment (including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD)), a single infusion of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) significantly improved the rate of minimal residual disease (MRD) negativity compared to standard therapies (pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd)). The MRD negativity rate is an important prognostic marker for prolonged survival in multiple myeloma patients. These results reinforce the clinical value of CARVYKTI as an early (second-line) treatment and support its recent overall survival (OS) benefits compared to standard therapies. The results regarding MRD negativity were presented orally at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) held in San Diego, California.